🇺🇸 FDA
Pipeline program

Invokana 100 mg film-coated tablets, Xigduo 5 mg/850 mg film-coated tablets, Vokanamet 150 mg/850 mg film-coated tablets, Forxiga 10 mg film-coated tablets, Vokanamet 50 mg/1,000 mg film-coated tablets, Invokana 300 mg film-coated tablets, Forxiga 5 mg film-coated tablets, Vokanamet 50 mg/850 mg film-coated tablets, Synjardy 12.5 mg/1,000 mg film-coated tablets, Synjardy 12.5 mg/850 mg film-coated tablets, Jardiance 25 mg film-coated tablets, Synjardy 5 mg/1,000 mg film-coated tablets, Xigduo 5 mg/1,000 mg

TRS-2019-00002051

Approved small_molecule active

Quick answer

Invokana 100 mg film-coated tablets, Xigduo 5 mg/850 mg film-coated tablets, Vokanamet 150 mg/850 mg film-coated tablets, Forxiga 10 mg film-coated tablets, Vokanamet 50 mg/1,000 mg film-coated tablets, Invokana 300 mg film-coated tablets, Forxiga 5 mg film-coated tablets, Vokanamet 50 mg/850 mg film-coated tablets, Synjardy 12.5 mg/1,000 mg film-coated tablets, Synjardy 12.5 mg/850 mg film-coated tablets, Jardiance 25 mg film-coated tablets, Synjardy 5 mg/1,000 mg film-coated tablets, Xigduo 5 mg/1,000 mg for Type 2 diabetes mellitus is a Approved program (small_molecule) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
Ology Bioservices Ireland LTD
Indication
Type 2 diabetes mellitus
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials